**Background of HOXB7 Antibody**
HOXB7. a member of the homeobox (HOX) gene family, encodes a transcription factor critical in embryonic development, cell differentiation, and tissue patterning. HOX proteins regulate gene expression by binding to DNA via their conserved homeodomain, influencing processes like proliferation, apoptosis, and migration. HOXB7. specifically, has been implicated in oncogenesis, with studies linking its overexpression to tumor progression in cancers such as breast, ovarian, melanoma, and leukemia. It promotes angiogenesis, metastasis, and chemoresistance by modulating pathways like ERK and Wnt/β-catenin.
HOXB7 antibodies are essential tools for detecting and quantifying HOXB7 protein levels in research and diagnostics. These antibodies enable techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study HOXB7's expression patterns, subcellular localization, and interactions in normal vs. diseased tissues. Commercially available HOXB7 antibodies are typically raised against specific epitopes, such as recombinant protein fragments or synthetic peptides, and validated for specificity and sensitivity.
Research using HOXB7 antibodies has highlighted its role as a potential biomarker or therapeutic target in cancer. For instance, elevated HOXB7 correlates with poor prognosis in breast cancer, suggesting its utility in risk stratification. Ongoing studies explore HOXB7 inhibition to disrupt oncogenic signaling, underscoring the antibody's importance in both mechanistic and translational contexts.